Free Androgen Index
Testosterone is the major androgen (sex hormone) in males. Its production is controlled by luteinizing hormone (LH), which is released from the anterior pituitary gland. Testosterone stimulates adult maturation of external genitalia and secondary sex characteristics such as the growth of beard and body hair. In addition, testosterone has anabolic (stimulating the growth of bone and muscle) effects leading to increased linear growth, nitrogen retention, and muscle development. Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of hypogonadal males.
Major causes of lowered testosterone in males include hypogonadotropic hypogonadism, testicular failure, therapeutic castration, hyperprolactinemia, hypopituitarism, some types of liver and kidney diseases, and critical illness. Testosterone levels are much lower in females compared to males. The major sources of testosterone in females are the ovaries, adrenal glands, and peripheral conversion of androstenedione.
In females, increased serum testosterone levels may be indicative of polycystic ovary syndrome or adrenal hyperplasia. The clinical manifestations of excess testosterone include infertility, hirsutism (excessive hairiness), amenorrhea (lack of menstruation) and obesity.
Most of the blood-circulating hormone is bound to proteins such as sex hormone-binding globulin (SHBG) and albumin. More than 60% of testosterone is bound to SHBG. SHBG-bound testosterone is not readily available for intracellular complex formation because of SHBG's strong binding affinity for testosterone. Thus, SHBG-bound testosterone is considered to be biologically inactive. Since albumin has lower binding affinity for testosterone, this form is easily available for use at target cells. The free testosterone is biologically active, and is rendered immediately active through its rapid dissociation from albumin. Therefore, the pool of free and weakly-bound testosterone is collectively called the "bioavailable" or "non-SHBG-bound" testosterone (NSB-T).
True androgen status can be assessed either by measuring free testosterone or by calculating the ratio of the total testosterone (TT) concentration to the concentration (or binding capacity) of SHBG. This ratio, which is a useful indicator of an abnormal androgen status, is called the free androgen index (FAI) or, sometimes, the testosterone free index (TFI). The index is used to estimate physiologically active testosterone and is calculated as the ratio of total testosterone divided by SHBG (both expressed in the same units) and multiplied by 100 to yield numerical results comparable in free testosterone concentration. The FAI is often increased in severe acne, male androgenic alopecia (balding), hirsutism, and other conditions in which a normal total testosterone level is found with a low SHBG level. In non-obese, nonhirsute oligomenorrheic women, an elevated FAI during the early follicular phase is reported to be a sensitive and specific indicator for polycystic ovarian diseases.
- The free androgen index can be used to estimate physiologically active testosterone
- Evaluation of LH secretion and Leydig cell function
- Evaluation of gonadal and adrenal function
- Diagnosis of hypogonadism in males and hirsutism and virilization in females
- Infertility (men and women
- Testicular tumors
- Hormone (testosterone) therapy monitoring in postmenopausal women
Increased in:
- Idiopathic sexual precocity (in boys, levels may be in adult range)
- Polycystic ovary syndrome (in females)
- Adrenal hyperplasia
- Adrenocortical tumors
- Trophoblastic disease during pregnancy
- Idiopathic hirsutism
- Virilizing ovarian tumors
- Arrhenoblastoma
- Virilizing luteoma
- Liver cirrhosis (through increased SHBG)
- Hyperthyroidism
- In some drugs such as anticonvulsants, barbiturates, estrogens, oral contraceptives (through increased SHBG)
Decreased in:
- Hypogonadism
- Orchidectomy
- Klinefelter syndrome
- Liver insufficiency
- In some drugs: digoxin, spironolactone, acarbose
Males: 30-150
Females: 7-10
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2532-40. [PMID: 21994406]
- S D J Med. 1998 Dec;51(12):449-51. [PMID: 9871405]
- Ann Clin Biochem. 1989 Jul;26 ( Pt 4):311-6. [PMID: 2764484]
- Ann Clin Biochem. 2006 Jan;43(Pt 1):3-12. [PMID: 16390603]
- Front Horm Res. 2009;37:21-31. [PMID: 19011286]
- Methods Mol Biol. 2006;324:197-211. [PMID: 16761380]
- Ann Clin Biochem. 1995 Jul;32 ( Pt 4):345-57. [PMID: 7486793]
- Ann Clin Biochem. 2006;43(Pt 1):3. [PMID: 16390603]
- Best Pract Res Clin Endocrinol Metab. 2006;20:177. [PMID: 16772150]